Oncology, CNS Agents May Dominate 2006 NME Approvals
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb’s multi-targeted kinase inhibitor dasatinib and Genta’s Bcl-2 inhibitor Genasense (oblimersen) could be approved for leukemia indications in the first half of 2006, if granted priority reviews. Both agents were submitted in late December.
You may also be interested in...
Altana Omnaris nasal spray approval
Altana's Omnaris (ciclesonide nasal spray) for the treatment of allergic rhinitis in adults and children 12 years of age and older clears FDA Oct. 23. Altana said it hopes to secure a marketing partner before introducing the new molecular entity; the firm's current goal is a 2007 launch. Omnaris is simultaneously "approvable" for use in children ages 2-11. An inhalation formulation of ciclesonide, developed with Sanofi-Aventis under the trade name Alvesco, has been approvable for asthma since 2004 (1Pharmaceutical Approvals Monthly January 2006, p. 13)...
Schering AG/Chiron Betaseron Label Expansion For Early MS Expected By Q4
Schering AG expects expanded approval of its multiple sclerosis therapy Betaseron in the fourth quarter to allow earlier use for newly emergent disease
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011